My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Bristol-Myers Squibb (NY:BMY)

54.42 -1.14 (-2.05%)

Streaming Delayed Price Updated: 2:43 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

85 86 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

Beating The September Curse–These 10 Stocks Shine While The S&P 500 Stumbles ↗

September 02, 2025

September is historically the worst month for stocks, but these 10 S&P 500 companies have consistently delivered gains.

Via Benzinga

Topics Stocks

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗

August 30, 2025

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Via Investor's Business Daily

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

August 29, 2025

From Bristol Myers Squibb

Via Business Wire

Price Over Earnings Overview: Bristol-Myers Squibb ↗

August 18, 2025

Via Benzinga

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025

From Bristol Myers Squibb

Via Business Wire

Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn

August 27, 2025

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)

August 26, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Profitable Stock Worth Investigating and 2 We Turn Down

August 26, 2025

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

August 25, 2025

From Bristol Myers Squibb

Via Business Wire

Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock with Strong Profitability and Growth Prospects ↗

August 25, 2025

Bristol-Myers Squibb (BMY) is a top dividend stock with a 5.12% yield, strong profitability, and a solid financial health rating, making it a compelling choice for income investors.

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 22, 2025

Via Benzinga

ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades' ↗

August 22, 2025

Malcolm Ethridge from Capital Area Planning Group sees potential in ServiceNow, Inc. despite recent dip. Bristol-Myers and Live Nation also highlighted.

Via Benzinga

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Identified as a Top Value Stock with Strong Fundamentals ↗

August 22, 2025

Bristol-Myers Squibb (BMY) is a top value stock with a low P/E ratio of 7.2, strong profitability, and a high 5.19% dividend yield.

Via Chartmill

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

August 19, 2025

Via Benzinga

How Do Investors Really Feel About Bristol-Myers Squibb? ↗

August 19, 2025

Via Benzinga

Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS ↗

August 16, 2025

Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2025

Via Benzinga

Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks ↗

August 13, 2025

The dividend stocks listed below all yield more than 5% and look like safe long-term buys.

Via The Motley Fool

BMY Q2 Deep Dive: Pipeline Progress, Guidance Revision, and Strategic Partnerships Shape Outlook

August 13, 2025

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue...

Via StockStory

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗

August 11, 2025

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to...

Via Benzinga

Topics Lawsuit

PRME Revenue Misses by 73% ↗

August 07, 2025

Via The Motley Fool

Is It Time to Buy Biotech Stocks? ↗

August 06, 2025

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Via The Motley Fool

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗

August 06, 2025

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.

Via Benzinga

Topics Lawsuit

1 Small-Cap Biotech Stock Poised for a Breakout ↗

August 06, 2025

This developmental biotech is nearing a key inflection point.

Via The Motley Fool

Topics Economy

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

August 04, 2025

From Bristol Myers Squibb

Via Business Wire

Why Is Replimune Stock Trading Lower On Monday? ↗

August 04, 2025

Replimune stock falls as FDA denies skin cancer drug approval and investors sue over alleged misstatements tied to the IGNYTE trial.

Via Benzinga

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth ↗

August 04, 2025

BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.

Via Benzinga

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

Via Investor Brand Network

Topics Government

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

85 86 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.